下肢血运重建后30天内院內与出院后主要不良事件的比较
基于美国外科医师学会国家外科质量改进计划2011至2015年血管靶向数据库,分析14125例下肢血运重建患者(LEB 8909例,PVI 5216例)30天内院内及出院后不良事件。结果显示多数主要不良事件发生在出院后,尤其在PVI后,仅统计院内数据会低估事件并可能高估PVI获益。
要点
- 30天主要不良事件在PVI后22%、LEB后31%,其中出院后发生占比PVI 56%、LEB 53%。
- CLTI患者30天死亡率PVI 2.3% vs LEB 2.1%,无显著差异,但院内死亡仅占PVI 43%、LEB 65%。
- 作者认为评估术后不良事件应报告30天而非仅院内结局。
核心结论
- 多数主要不良事件在PVI后发生率低于LEB,但下肢血运重建后相当数量主要不良事件发生在出院后,尤其在PVI后。
- 若仅评估院内数据可能高估PVI相对于LEB的获益,作者认为评估术后不良事件应报告30天而非院内结局。
研究设计与样本
- 使用美国外科医师学会国家外科质量改进计划2011至2015年血管靶向数据库,纳入因间歇性跛行和慢性肢体威胁性缺血(CLTI)行下肢旁路(LEB)或经皮血管介入(PVI)的患者。
- 共14125例患者,LEB 8909例(63%),PVI 5216例(37%),统计30天院内及出院后不良事件。
主要发现
- CLTI患者30天总死亡率PVI 2.3% vs LEB 2.1%(P=0.61),院内死亡仅占PVI死亡的43%、LEB死亡的65%(P≤0.001)。
- 主要不良心脏事件PVI 2.9% vs LEB 4.6%(P<0.001),出院后事件占比PVI 37% vs LEB 18%(P≤0.001)。
- 30天再手术率PVI 14% vs LEB 18%(P<0.001),出院后发生占比PVI 46% vs LEB 44%(P=0.55)。
- 任何术后主要不良事件PVI 22% vs LEB 31%,出院后发生占比PVI 56% vs LEB 53%(P=0.17)。
- 跛行患者30天总死亡率PVI 0.4% vs LEB 0.7%(P=0.32),出院后发生占比PVI 90% vs LEB 50%(P=0.049);30天再手术率PVI 5.2% vs LEB 8.0%(P<0.001),出院后发生占比PVI 63% vs LEB 53%(P=0.09);任何主要不良事件PVI 7.0% vs LEB 17%,出院后发生占比PVI 65% vs LEB 63%(P=0.66)。
临床怎么用
- 作者认为评估下肢血运重建术后不良事件时应报告30天结局而非仅院内结局,以真实反映PVI与LEB的相对获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Studies using hospital discharge data likely underestimate postoperative morbidity and mortality after lower extremity revascularization because they fail to capture postdischarge events. However, the degree of underestimation and the timing of postdischarge complications are not well-characterized. METHODS: We used the American College of Surgeons National Surgical Quality Improvement Program procedure-targeted vascular databases from 2011 to 2015 to tabulate 30-day adverse events (in hospital and after discharge) for lower extremity bypass (LEB) and percutaneous vascular interventions (PVIs) performed for claudication and chronic limb-threatening ischemia (CLTI). RESULTS: A total of 14,125 patients underwent lower extremity revascularization, 8909 patients (63%) with LEB and 5216 (37%) with PVI. For CLTI, total 30-day mortality was similar between PVI and LEB (2.3% vs 2.1%; P = .61), but in-hospital deaths only accounted for 43% of PVI mortality and only 65% of LEB mortality (P ≤ .001). Major adverse cardiac events occurred in 2.9% of PVI patients and 4.6% of LEB patients (P < .001), with postdischarge events accounting for 37% of PVI events and 18% of LEB (P ≤ .001). Although the 30-day reoperation rates were 14% for PVI and 18% for LEB (P < .001), almost one-half occurred after discharge (PVI 46% vs LEB 44%; P = .55). Any postoperative major adverse events (MAEs) occurred in 22% of patients after PVI and 31% after LEB, with more than one-half occurring after discharge (PVI 56% vs LEB 53%; P = .17). For claudicants, total 30-day mortality was 0.4% for PVI and 0.7% for LEB (P = .32), with the vast majority of events occurring after discharge (PVI 90% vs LEB 50%; P = .049). The 30-day reoperation rates were 5.2% for PVI and 8.0% for LEB (P < .001), with more than one-half occurring after discharge (PVI 63% vs LEB 53%; P = .09). Any MAEs occurred in 7.0% of patients after PVI and 17% after bypass, with the majority occurring after discharge (PVI 65% vs LEB 63%; P = .66). CONCLUSIONS: Most MAEs occur less frequently after PVI than LEB. However, a significant number of major of adverse events after lower extremity revascularization occur after leaving the hospital, especially after PVI, which may overestimate its benefits compared with LEB if only in-hospital data are evaluated. These data demonstrate the importance of reporting 30-day rather than in-hospital outcomes when evaluating postoperative adverse events.
引用
- Liang P, Li C, O'Donnell TFX, et al. In-hospital versus postdischarge major adverse events within 30 days following lower extremity revascularization. J Vasc Surg. 2018. PMID: 30301689. doi:10.1016/j.jvs.2018.06.207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。